Zydus Lifesciences Launches Biosimilar Eye Drug, Plans Day-One Semaglutide Generic

Zydus Lifesciences has launched ANYRA, India's first indigenously developed biosimilar of Aflibercept 2 mg, targeting critical retinal conditions including wet age-related macular degeneration, diabetic retinopathy, and diabetic macular edema. The company has also secured approval from the Drug Controller General of India to manufacture and market semaglutide for Type-2 diabetes and obesity, positioning itself for a day-one commercial debut in March 2026 when the patent expires.

The introduction of ANYRA is poised to address a major challenge in India: the high cost of advanced biological treatments, thereby expanding patient access to quality care. With over 100 million diabetics in India, this development represents a significant step in accessible healthcare solutions. Zydus reached an agreement with Regeneron Pharmaceuticals and Bayer for Anyra.

The global market for Aflibercept, the active ingredient in the reference drug Eylea, was valued at approximately $5.89 billion in 2023. With the patent expiry of such innovator drugs, the development of biosimilars like ANYRA opens avenues for increased competition and potentially lower prices. Zydus's entry into this segment signifies its commitment to expanding its biologics business, which already includes successful launches like the Nivolumab biosimilar (Tishtha) for cancer treatment.

The Zydus semaglutide generic will be marketed under three brand names: Semaglyn, Mashema, and Altreme. The drug will be available in 1.5 mg strength and delivered via a reusable, adjustable pen device. Unlike conventional single-use injection pens, this system allows patients to dial different doses from a single pen by using replaceable cartridges.

One of the most distinguishing features of the Zydus semaglutide generic is its reusable pen delivery system. Instead of discarding the entire device after a single cycle, patients can retain the pen and simply replace the cartridge. This approach offers cost efficiency through reduced device replacement and supports environmentally responsible healthcare practices by generating less plastic waste.

By obtaining regulatory clearance ahead of the patent expiry, Zydus has positioned itself for immediate market entry. This day-one launch strategy enables the company to capture early market share while addressing India's growing burden of metabolic disorders. India has witnessed a steady rise in Type-2 diabetes and obesity cases, and the availability of a lower-cost semaglutide alternative could significantly expand treatment coverage across urban and semi-urban populations.

The company received a closeout letter from the FDA in January 2026, resolving a previous warning letter and indicating that corrective actions had been accepted. The company's shares experienced a slight rise, trading at Rs 910.25 each on the BSE.